Physician
Bethany Medical Center
Bethany Medical Center was paid $3.77M by Medicaid between Jan 2018 and Dec 2024, across 94 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 48% of everything it billed.
33Billing provider infoBETHANY MEDICAL CENTER
HIGH POINT, NC 27265
HIGH POINT, NC 27265
33aNPI1255880571assigned 09/28/2016
33bProvider typePlastic Surgery Physician
28Total paid$3.77M
24GClaims211,525
24DCodes billed94
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Plastic Surgery Physician providers in North Carolina
Rank by total paid#1 of 7
Median peer was paid$177K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PETERS, LENIN controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,820 | $183K | |
| 2019 | 11,414 | $259K | |
| 2020 | 15,197 | $327K | |
| 2021 | 29,734 | $670K | |
| 2022 | 42,192 | $816K | |
| 2023 | 51,404 | $803K | |
| 2024incomplete | 50,764 | $708K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 48% | 34,495 | 26,132 | $1.82M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 13,004 | 9,769 | $432K |
| 99199 | Unlisted special service, procedure or report | 5.2% | 31,902 | 19,470 | $196K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.9% | 2,325 | 1,958 | $148K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.9% | 2,204 | 1,666 | $147K |
| 94375 | 3.4% | 7,998 | 6,218 | $127K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 1,463 | 1,200 | $111K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.8% | 1,085 | 935 | $106K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 995 | 707 | $64K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 6,671 | 3,912 | $63K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 2,065 | 1,510 | $53K |
| 99406 | 1.3% | 7,921 | 6,130 | $50K |
82 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 861 | $36K |
| 83970 | <1% | 719 | $32K | |
| 99442 | <1% | 831 | $26K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 374 | $24K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 744 | $23K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,943 | $23K |
| 93000 | <1% | 2,233 | $21K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 985 | $21K |
| 86769 | <1% | 531 | $20K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,364 | $18K |
| 99401 | <1% | 741 | $17K | |
| 91200 | <1% | 808 | $15K | |
| 80061 | Lipid panel | <1% | 943 | $13K |
| 80053 | Comprehensive metabolic panel | <1% | 1,317 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,312 | $11K |
| 81025 | <1% | 1,765 | $10K | |
| 82962 | <1% | 7,248 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 237 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 769 | $7K |
| 84480 | <1% | 464 | $7K | |
| 99443 | <1% | 125 | $7K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 57 | $5K |
| 46221 | <1% | 83 | $5K | |
| 82607 | <1% | 315 | $5K | |
| 90756 | <1% | 471 | $5K | |
| 84439 | <1% | 490 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 282 | $5K |
| 82746 | <1% | 300 | $4K | |
| 82728 | <1% | 315 | $4K | |
| 72100 | <1% | 273 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 733 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 94 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 43 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 80 | $4K |
| 81002 | <1% | 2,909 | $3K | |
| 83550 | <1% | 315 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 29 | $3K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $2K |
| 86703 | <1% | 212 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 129 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 851 | $2K |
| 83540 | <1% | 296 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,264 | $1K |
| 73630 | <1% | 248 | $1K | |
| 82044 | <1% | 525 | $1K | |
| 11721 | <1% | 408 | $1K | |
| 86803 | <1% | 70 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,379 | $751.10 |
| 90688 | <1% | 216 | $737.55 | |
| 87340 | <1% | 70 | $642.88 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 302 | $574.33 |
| 96103 | <1% | 559 | $435.38 | |
| 96146 | <1% | 1,731 | $415.27 | |
| 80050 | General health panel | <1% | 30 | $318.64 |
| 3044F | <1% | 3,285 | $260.00 | |
| 83735 | <1% | 37 | $246.92 | |
| 90661 | <1% | 29 | $195.90 | |
| 99490 | Ccm add 20min | <1% | 48 | $158.03 |
| 86431 | <1% | 12 | $84.00 | |
| 84550 | <1% | 12 | $66.84 | |
| 3079F | <1% | 2,991 | $17.49 | |
| 2028F | <1% | 208 | $8.66 | |
| 3008F | 0% | 11,814 | $0.00 | |
| 3075F | 0% | 1,150 | $0.00 | |
| 3049F | 0% | 1,355 | $0.00 | |
| 3048F | 0% | 2,653 | $0.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 964 | $0.00 |
| 1125F | 0% | 227 | $0.00 | |
| 3074F | 0% | 7,319 | $0.00 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 0% | 209 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 336 | $0.00 |
| 1170F | 0% | 76 | $0.00 | |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 0% | 66 | $0.00 |
| 3078F | 0% | 6,673 | $0.00 | |
| 3077F | 0% | 776 | $0.00 | |
| 3288F | 0% | 101 | $0.00 | |
| 4004F | 0% | 1,714 | $0.00 | |
| 3050F | 0% | 462 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 79 | $0.00 |
| 11056 | 0% | 29 | $0.00 | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 0% | 281 | $0.00 |
| 1159F | 0% | 83 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETERS, LENIN (DIRECTOR OF CONTRACTING AND CREDENT)
| Provider | Location | Paid |
|---|---|---|
| Bethany Medical Center | High Point, NC | $18.31M |
| Bethany Medical Center | Greensboro, NC | $7.28M |
| Bethany Medical Center | Greensboro, NC | $5.72M |
| Bethany Medical Center | Winston Salem, NC | $5.13M |
| Bethany Medical Center | Winston Salem, NC | $4.74M |
| Bethany Medical Center | Kernersville, NC | $2.29M |
| Bethany Medical Center | Greensboro, NC | $1.70M |
| Bethany Medical Center | Kernersville, NC | $1.62M |
| Bethany Medical Center | Mount Airy, NC | $1.50M |
| Bethany Medical Center, PA | High Point, NC | $1.47M |
| Bethany Medical Center PA | High Point, NC | $1.25M |
| Bethany Medical Center PA | High Point, NC | $1.13M |
| Bethany Medical Center, PA | High Point, NC | $645K |
| Bethany Medical Center | High Point, NC | $524K |
| LJP Anesthesia Services, PLLC | High Point, NC | $198K |
| Bethany Medical Center | High Point, NC | $88K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.